Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
Clinicians highlight the need to educate patients about warning signs
Immune checkpoint inhibitor and oncolytic viral immunotherapy produce synergistic effect
Companion studies reveal efficacy indicators for PD-1/PD-L1 inhibition
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy